Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers

Exclusion Criteria

• •History of aspirin use 1-14 days prior to screening
• •NSAID (ibuprofen, naprosyn, meloxicam, etc) use 1-7 days prior to screening
• •Inhaled glucocorticoid use 1-7 days prior to screening
• •Systemic glucocorticoid use 1-14 days prior to screening
• •History of peptic ulcer disease
• •Current or recent clinically significant bleeding
• •Allergy, intolerance or contraindication to aspirin or NSAID use
• •Thrombocytopenia (platelet count \< 100,000) in 30 days prior to screening visit
• •Severe hepatic insufficiency
• •GFR \< 30 mL/min/1.73 m2 in 30 days prior to screening visit
• •History of aspirin or celecoxib allergy
• •Elevated INR (\>1.5) in 30 days prior to screening visit
• •Current diagnosis of malignancy or history of non-skin malignancy in last 5 years
• •Current use of systemic anticoagulants (e.g., warfarin (Coumadin), enoxaparin (Lovenox), Fondaparinux (Arixtra), dabigatran (Pradaxa))
• •Diagnosis of COPD
• •Intake of \> 250 mg of fish oil supplementation daily